{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:07:38Z","timestamp":1776978458915,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,18]]},"DOI":"10.7759\/cureus.82549","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:50:32Z","timestamp":1745038232000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Vildagliptin Sustained-Release and Metformin Sustained-Release Fixed-Dose Combination in Indian Patients With Type 2 Diabetes Mellitus: A Real-World Perspective"],"prefix":"10.7759","author":[{"given":"Archana","family":"Sarda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Sosale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Jagan Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehal","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Langade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Kotwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Kolapkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230413094200","article-title":"Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th edition","volume":"20","author":"Kumar A","year":"2024","unstructured":"Kumar A, Gangwar R, Zargar AA, Kumar R, Sharma A. Prevalence of diabetes in India: a review of IDF Diabetes Atlas 10th edition. Curr Diabetes Rev. 2024, 20:e130423215752. 10.2174\/1573399819666230413094200","journal-title":"Curr Diabetes Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2021.02.016","article-title":"Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults","volume":"58","author":"Ranasinghe P","year":"2021","unstructured":"Ranasinghe P, Jayawardena R, Gamage N, Sivanandam N, Misra A. Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults. Ann Epidemiol. 2021, 58:128-48. 10.1016\/j.annepidem.2021.02.016","journal-title":"Ann Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.748157","article-title":"Prevalence, awareness, treatment and control of diabetes in India from the countrywide national NCD monitoring survey","volume":"10","author":"Mathur P","year":"2022","unstructured":"Mathur P, Leburu S, Kulothungan V. Prevalence, awareness, treatment and control of diabetes in India from the countrywide national NCD monitoring survey. Front Public Health. 2022, 10:748157. 10.3389\/fpubh.2022.748157","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al.. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz B","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019, 10:389. 10.3389\/fendo.2019.00389","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v13.i2.85","article-title":"Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment","volume":"13","author":"Florentin M","year":"2022","unstructured":"Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes. 2022, 13:85-96. 10.4239\/wjd.v13.i2.85","journal-title":"World J Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023, 46:S140-57. 10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0199-3","article-title":"Vildagliptin: a review of its use in type 2 diabetes mellitus","volume":"74","author":"Keating GM","year":"2014","unstructured":"Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2014, 74:587-610. 10.1007\/s40265-014-0199-3","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/11795514231203911","article-title":"Expert evaluation of efficacy and rationality of vildagliptin \u201cever-vilda\u201d: an Indian perspective","volume":"17","author":"Kalra S","year":"2024","unstructured":"Kalra S, Zargar AH, Sridhar GR, et al.. Expert evaluation of efficacy and rationality of vildagliptin \u201cever-vilda\u201d: an Indian perspective. Clin Med Insights Endocrinol Diabetes. 2024, 17:11795514231203911. 10.1177\/11795514231203911","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2014.1545","article-title":"A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus","volume":"7","author":"Su Y","year":"2014","unstructured":"Su Y, Su YL, Lv LF, Wang LM, Li QZ, Zhao ZG. A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Exp Ther Med. 2014, 7:799-803. 10.3892\/etm.2014.1545","journal-title":"Exp Ther Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.07.016","article-title":"Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus","volume":"67","author":"Str\u00f3zik A","year":"2015","unstructured":"Str\u00f3zik A, St\u0119posz A, Basiak M, Dro\u017cd\u017c M, Okopie\u0144 B. Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Pharmacol Rep. 2015, 67:24-31. 10.1016\/j.pharep.2014.07.016","journal-title":"Pharmacol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39204","article-title":"Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review","volume":"15","author":"Sridhar GR","year":"2023","unstructured":"Sridhar GR, Pandit K, Warrier S, Birla A. Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review. Cureus. 2023, 15:e39204. 10.7759\/cureus.39204","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13020045","article-title":"Metformin sustained-release and vildagliptin fixed-dose combination for optimizing glycemic control: a review with real-world case reports","volume":"13","author":"Chawla M","year":"2023","unstructured":"Chawla M, Chawla P, Jethwani P, Shah K, Reddy S. Metformin sustained-release and vildagliptin fixed-dose combination for optimizing glycemic control: a review with real-world case reports. Clin Pract. 2023, 13:497-504. 10.3390\/clinpract13020045","journal-title":"Clin Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s2503","article-title":"Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet","volume":"4","author":"Halimi S","year":"2008","unstructured":"Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag. 2008, 4:481-92. 10.2147\/vhrm.s2503","journal-title":"Vasc Health Risk Manag"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14497","article-title":"Pharmacological management of South Asians with type 2 diabetes: consensus recommendations from the South Asian Health Foundation","volume":"38","author":"Hanif W","year":"2021","unstructured":"Hanif W, Ali SN, Bellary S, et al.. Pharmacological management of South Asians with type 2 diabetes: consensus recommendations from the South Asian Health Foundation. Diabet Med. 2021, 38:e14497. 10.1111\/dme.14497","journal-title":"Diabet Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00926-7","article-title":"Insights from verify: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes","volume":"11","author":"Matthews D","year":"2020","unstructured":"Matthews D, Del Prato S, Mohan V, et al.. Insights from verify: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020, 11:2465-76. 10.1007\/s13300-020-00926-7","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12128","article-title":"Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence","volume":"16","author":"Liu Y","year":"2014","unstructured":"Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab. 2014, 16:111-7. 10.1111\/dom.12128","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.667078","article-title":"Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus","volume":"13","author":"Guarino E","year":"2012","unstructured":"Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother. 2012, 13:1377-84. 10.1517\/14656566.2012.667078","journal-title":"Expert Opin Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1476333","article-title":"Initial combination therapy with vildagliptin plus metformin in drug-na\u00efve patients with T2DM: a 24-week real-life study from Asia","volume":"34","author":"Chawla M","year":"2018","unstructured":"Chawla M, Kim TH, Mirasol RC, Faruque P, Cooke K, Hours-Zesiger P, Shete A. Initial combination therapy with vildagliptin plus metformin in drug-na\u00efve patients with T2DM: a 24-week real-life study from Asia. Curr Med Res Opin. 2018, 34:1605-11. 10.1080\/03007995.2018.1476333","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews DR","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019, 394:1519-29. 10.1016\/S0140-6736(19)32131-2","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14192","article-title":"Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study","volume":"23","author":"Chan JC","year":"2021","unstructured":"Chan JC, Pald\u00e1nius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021, 23:245-51. 10.1111\/dom.14192","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202204_28611","article-title":"Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis","volume":"26","author":"Ding Y","year":"2022","unstructured":"Ding Y, Liu Y, Qu Y, et al.. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2022, 26:2802-17. 10.26355\/eurrev_202204_28611","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12233","article-title":"Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis","volume":"16","author":"Phung OJ","year":"2014","unstructured":"Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014, 16:410-7. 10.1111\/dom.12233","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01040.x","article-title":"Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus","volume":"11","author":"Bosi E","year":"2009","unstructured":"Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009, 11:506-15. 10.1111\/j.1463-1326.2009.01040.x","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12078","article-title":"Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study","volume":"6","author":"Chatterjee S","year":"2014","unstructured":"Chatterjee S, Chatterjee S. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study. J Diabetes. 2014, 6:237-42. 10.1111\/1753-0407.12078","journal-title":"J Diabetes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S315227","article-title":"Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study","volume":"14","author":"Mohan V","year":"2021","unstructured":"Mohan V, Zargar A, Chawla M, et al.. Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study. Diabetes Metab Syndr Obes. 2021, 14:2925-33. 10.2147\/DMSO.S315227","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v12i6.5760","article-title":"A comparative pharmacodynamic and pharmacokinetic study of vildagliptin SR 100 mg tablet in normal healthy adult male subjects","volume":"12","author":"Warrier S","year":"2022","unstructured":"Warrier S, Joshi HR, Joshi N. A comparative pharmacodynamic and pharmacokinetic study of vildagliptin SR 100 mg tablet in normal healthy adult male subjects. J Drug Deliv Therapeut. 2022, 12:22-6. 10.22270\/jddt.v12i6.5760","journal-title":"J Drug Deliv Therapeut"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/335664-efficacy-and-safety-of-vildagliptin-sustained-release-and-metformin-sustained-release-fixed-dose-combination-in-indian-patients-with-type-2-diabetes-mellitus-a-real-world-perspective","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:50:33Z","timestamp":1745038233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/335664-efficacy-and-safety-of-vildagliptin-sustained-release-and-metformin-sustained-release-fixed-dose-combination-in-indian-patients-with-type-2-diabetes-mellitus-a-real-world-perspective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.82549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}